PAVmed (PAVM) Net Income towards Common Stockholders (2016 - 2025)

PAVmed's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$1.9 million for Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 238.04% year-over-year to -$1.9 million in Q4 2025; TTM through Dec 2025 was -$3.8 million, a 88.26% increase from a year earlier, with the FY2025 full-year figure at -$3.8 million, down 111.89% from the prior year.
• Net Income towards Common Stockholders climbed to -$1.9 million in Q4 2025 per PAVM's latest filing, from -$6.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $17.7 million in Q1 2025 and bottomed at -$26.2 million in Q3 2022.
• The 5-year median for Net Income towards Common Stockholders is -$14.6 million (2023), against an average of -$12.8 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 177.65% in 2025; the steepest drop was 238.04% in 2025.
• Year by year, Net Income towards Common Stockholders stood at -$17.3 million in 2021, then slipped by 18.79% to -$20.5 million in 2022, then gained by 22.54% to -$15.9 million in 2023, then jumped by 108.46% to $1.3 million in 2024, then sank by 238.04% to -$1.9 million in 2025.
• Per Business Quant, the three latest PAVM Net Income towards Common Stockholders figures stand at -$1.9 million (Q4 2025), -$6.3 million (Q3 2025), and -$13.3 million (Q2 2025).